The Technical Analyst
Pharvaris N.V. [PHVS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Pharvaris N.V. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
7.38% $24.45
America/New_York / 26 apr 2024 @ 12:22
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 315.82 mill |
| EPS: | -2.81 |
| P/E: | -8.70 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 53.82 mill |
| Avg Daily Volume: | 0.0911 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.70 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.48x |
| Company: PE -8.70 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$10.93 (-55.30%) $-13.52 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 22.47 - 26.24 ( +/- 7.73%) |
| ATR Model: 14 days |
Forecast:
14:01 - $24.94
Live Trading Signals (every 1 min)
Forecast
1: 12:31 - $24.39
Forecast 2: 13:21 - $24.84
Forecast 3: 14:01 - $24.94
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $24.45 (7.38% ) |
| Volume | 0.0422 mill |
| Avg. Vol. | 0.0911 mill |
| % of Avg. Vol | 46.35 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PHVS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:09 | sell | $28.77 | N/A | Active |
|---|
PHVS
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Latest Press Releases
2024-04-10 16:10:00 - Press Release
Pharvaris Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
Zug, switzerland, april 10, 2024 (globe newswire) -- pharvaris (nasdaq: phvs), a late-stage biopharmaceutical company developing novel, oral bradykinin b2 receptor antagonists to treat and prevent hereditary angioedema (hae) attacks, today reported financial results for the fourth quarter and year ended december 31, 2023 and provided a business update.
2024-04-10 16:08:00 - Press Release
Pharvaris Appoints David Nassif, J.d., As Chief Financial Officer
Zug, switzerland, april 10, 2024 (globe newswire) -- pharvaris (nasdaq: phvs), a late-stage biopharmaceutical company developing novel, oral bradykinin b2 receptor antagonists to treat and prevent hereditary angioedema (hae) attacks, today announced the appointment of david nassif, j.d., as chief financial officer, effective april 15, 2024. in this role, he will be responsible for refining and implementing pharvaris' corporate financial strategy and activities including financial reporting and operations. mr. nassif joins pharvaris with more than 30 years of experience in financial management, strategic planning, mergers and acquisitions, investor relations, legal, and capital allocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies.
2024-04-04 06:50:00 - Press Release
Pharvaris To Present Deucrictibant Clinical Data At The Ciic Spring 2024 Conference
Zug, switzerland, april 04, 2024 (globe newswire) -- pharvaris (nasdaq: phvs), a late-stage biopharmaceutical company developing novel, oral bradykinin b2 receptor antagonists to treat and prevent hereditary angioedema (hae) attacks, today announced the acceptance of two abstracts for presentation at the consortium of independent immunology clinics (ciic) spring 2024 conference, to be held from april 12-13, 2024, in arlington, tx.
2024-03-18 06:50:00 - Press Release
Pharvaris Announces Phase 3 Clinical Study Design For Recently Initiated Rapide-3 Study, And Presents Quality-of-life Improvement And Caregiver Behavior Data At Two Recent Hae Congresses
Zug, switzerland, march 18, 2024 (globe newswire) -- pharvaris (nasdaq: phvs), a late-stage biopharmaceutical company developing novel, oral bradykinin b2 receptor antagonists to treat and prevent hereditary angioedema (hae) attacks, presented at two recent congresses: the 3rd national congress of the italian network for hereditary and acquired angioedema (itaca) and the 2024 hae international (haei) regional conference americas.
2024-03-06 06:50:00 - Press Release
Pharvaris To Present Deucrictibant Clinical Data At Upcoming Congresses
Zug, switzerland, march 06, 2024 (globe newswire) -- pharvaris (nasdaq: phvs), a clinical-stage company developing novel, oral bradykinin b2 receptor antagonists to treat and prevent hereditary angioedema (hae) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd national congress of the italian network for hereditary and acquired angioedema (itaca), to be held from march 14-16, 2024, in milan, italy, and the 2024 hae international (haei) regional conference americas, to be held from march 15-17, 2024, in panama city, panama. details of the presentations are as follows:
Latest News
2024-04-04 06:50:00 - GlobeNewsWire
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.
2024-03-06 06:50:00 - GlobeNewsWire
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA), to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas, to be held from March 15-17, 2024, in Panama City, Panama. Details of the presentations are as follows:
2024-01-26 06:50:00 - GlobeNewsWire
Pharvaris to Present at the WSAAI Annual Meeting 2024
ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024, at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii.
2024-01-23 10:36:17 - Zacks Investment Research
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.
2023-12-07 16:33:12 - Zacks Investment Research
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.
2023-12-06 10:16:16 - InvestorPlace
Why Is Pharvaris (PHVS) Stock Up 36% Today?
Pharvaris (NASDAQ: PHVS ) stock is rising higher on Wednesday after the clinical-stage biopharmaceutical company announced an underwritten offering for its shares. That offering includes 11,125,000 shares of PHVS stock sold to one investor for a price of $24 each.
2023-12-06 08:12:00 - Market Watch
Pharvaris shares surge as treatment for severe swelling meets clinical trial goal
Shares of Pharvaris N.V. PHVS, +14.98% jumped 40% premarket on Wednesday after the Switzerland-based company said an investigational drug met its primary goal in a clinical trial for treatment and prevention of hereditary angioedema attacks.
2023-11-30 06:50:00 - GlobeNewsWire
Pharvaris to Present at the GA²LEN UCARE Conference 2023
ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of one abstract for oral presentation and two abstracts for poster presentation at the GA²LEN UCARE Conference 2023, to be held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil.
2023-10-30 06:50:00 - GlobeNewsWire
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2023 Annual Scientific Meeting, to be held from November 9-13, 2023, at the Anaheim Convention Center in Anaheim, CA.
2023-10-13 06:50:00 - GlobeNewsWire
Pharvaris To Present at the APAAACI 2023 International Conference
ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of an abstract oral presentation at the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) and Allergy and Clinical Immunology Society of Singapore (ACIS) APAAACI 2023 International Conference, to be held from October 23-26, 2023, at the Suntec Singapore International Convention and Exhibition Center in Singapore.